<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03022903</url>
  </required_header>
  <id_info>
    <org_study_id>F150128007</org_study_id>
    <nct_id>NCT03022903</nct_id>
  </id_info>
  <brief_title>Blue Light Photodynamic Therapy Treatment for Distal and Lateral Subungual Toenail Onychomycosis</brief_title>
  <official_title>Blue Light Photodynamic Therapy Treatment for Distal and Lateral Subungual Toenail Onychomycosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>DUSA Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study will evaluate the safety and efficacy of using blue light photodynamic
      therapy (PDT) for treating toenail fungal infections.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This research study will evaluate the safety and efficacy of using blue light photodynamic
      therapy (PDT) for treating toenail fungal infections.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects diagnosed with presence of subungual culture after 3rd treatment session</measure>
    <time_frame>3 weeks after baseline</time_frame>
    <description>Based on presence of fungal infection from culture assessment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with clinical cure based on photographs after the 3rd treatment session</measure>
    <time_frame>3 weeks after baseline</time_frame>
    <description>Based on visual assessment of photographs: presence or absence of fungal infection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare rates of mycological and clinical cure after three treatments between two groups with different ALA incubation times</measure>
    <time_frame>3 weeks after baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the durability of treatment outcomes with subungual culture and photographs at 24 weeks</measure>
    <time_frame>24 weeks after first treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate tolerability to treatment using a Visual Analog Scale (VAS) pain scale questionnaire at each treatment visit</measure>
    <time_frame>1 week after baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate tolerability to treatment using a Visual Analog Scale (VAS) pain scale questionnaire at each treatment visit</measure>
    <time_frame>2 weeks after baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate tolerability to treatment using a Visual Analog Scale (VAS) pain scale questionnaire at each treatment visit</measure>
    <time_frame>3 weeks after baseline</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Toenail Onychomycosis</condition>
  <arm_group>
    <arm_group_label>Photodynamic Therapy (PDT)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>PDT with ALA (photosensitizer) for 3 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Aminolevulinic Acid (ALA)</intervention_name>
    <description>Photosensitizing</description>
    <arm_group_label>Photodynamic Therapy (PDT)</arm_group_label>
    <other_name>ALA is a topical drug used in the administration of PDT.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients older than 19 and younger than 70 years

          -  Give written informed consent prior to any study procedures being conducted, and
             candidates will authorize the release and use of protected health information (PHI)

          -  Diagnosed with DLSO of the great toe with both positive KOH and positive culture
             growth of Trichophyton rubrum

          -  No topical treatment for DLSO in the preceding 2 weeks and no oral treatment for DLSO
             (itraconazole or terbinafine) in the preceeding 8 weeks

          -  At lease 20% of target great toe nail affected

        Exclusion Criteria:

          -  Unable to comply with the protocol (as defined y the investigator; i.e. drug or
             alcohol abuse or history of noncompliance)

          -  Patients with active nail disease that would confound evaluation of DLSO, such as
             psoriasis

          -  Patients with greater than 6 toenails affected

          -  Over 90% of target great toe affected

          -  Evidence of fingernail fungal infection

          -  Patients with recurrent serious infections or have been hospitalized in the preceding
             6 months for infection

          -  Patients with known history of HIV or hepatitis B or C infection

          -  Patients with severe, progressive, or uncontrolled with renal, hepatic, hematological,
             gastrointestinal, metabolic, endocrine, pulmonary, cardiovascular, or neurologic
             disease

          -  Any subject who, in the opinion of the investigator, will be uncooperative or unable
             to comply with study procedures
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boni E Elewski, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ramona Reeves</last_name>
    <phone>(205) 996-7546</phone>
    <email>mreeves@uab.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Kirklin Clinic</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Boni Elewski, MD</last_name>
      <phone>205-502-9962</phone>
      <email>dermresearch@uabmc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 16, 2015</study_first_submitted>
  <study_first_submitted_qc>January 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2017</study_first_posted>
  <last_update_submitted>January 29, 2018</last_update_submitted>
  <last_update_submitted_qc>January 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Boni Elewski, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Onychomycosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aminolevulinic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

